Research Analysts Issue Forecasts for FOLD Q1 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Investment analysts at Zacks Research issued their Q1 2025 earnings estimates for shares of Amicus Therapeutics in a research report issued on Tuesday, April 1st. Zacks Research analyst R. Department forecasts that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' Q3 2026 earnings at $0.11 EPS.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Wells Fargo & Company lowered their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD traded down $0.29 during midday trading on Thursday, hitting $6.86. The company's stock had a trading volume of 1,051,602 shares, compared to its average volume of 2,534,778. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock's 50 day simple moving average is $9.07 and its 200 day simple moving average is $9.81. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -38.14, a PEG ratio of 1.51 and a beta of 0.79. Amicus Therapeutics has a fifty-two week low of $6.84 and a fifty-two week high of $12.65.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Virtus Fund Advisers LLC bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $29,000. Covestor Ltd grew its position in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Amicus Therapeutics in the third quarter valued at $55,000. GF Fund Management CO. LTD. acquired a new position in Amicus Therapeutics during the fourth quarter worth $59,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Amicus Therapeutics by 1,610.8% during the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.